At the American Diabetes Association's 78th Annual Scientific Session, MD Mag spoke with Murrary Stewart, MD, the executive vice president and head of research and development at Novelion Therapeutics, about his and colleagues work looking at the effects of adding leptin to patients who were obese with low leptin levels. A long misunderstood hormone, Stewart discussed the findings of the trial and what they mean for clinicians.
